Dental alignment, regeneration and repair

Source date: 2026-11-05. Recorded in this review: November 10, 2026. Evidence: Peer-reviewed randomized trial; original abstract appraised.

A single-center, double-blind study randomized 40 patients aged 13–24 to low-level laser treatment or sham during fixed orthodontics. Root resorption occurred in both groups over 12 months. Most comparisons showed no between-group difference; two tooth/time comparisons showed greater resorption with laser. Small numbers and multiple comparisons prevent a firm conclusion of added harm.

Leveling/alignment took 123.8 versus 126.2 days (P=.487), providing no demonstrated acceleration. Short-term pain scores favored laser (P<.001 at most assessed early time points), but the abstract omits effect sizes and uncertainty intervals. Pain relief should not be equated with root preservation or faster completed orthodontic treatment.

Full methods, detailed harm tables and a matched prospective registration remain unappraised. The study does not address long-term retention/relapse or establish a new U.S. authorization.

Next: Full-paper appraisal and longer-term outcomes; no verified release date.

Sources: PubMed · PMID 42988646; DOI · 10.1016/j.ejwf.2026.08.003.

Source date: 2026-11-09. Recorded in this review: November 10, 2026. Evidence: Retrospective registration of a completed materials study; no results.

NCT07926035 reports a completed 12-person randomized within-person comparison of TC-85 and TA-28 directly printed aligner resins, worn in opposing arches for two weeks. Retrieved aligners are compared with unused material for hardness, elasticity, optical properties, surface structure and chemical conversion. The registry explicitly states that no tooth-movement outcomes were assessed.

The study ran from February to September 2026 but was first posted November 9. It has no posted results. Its structured crossover label conflicts with the simultaneous split-mouth narrative, and some manufacturing/protocol details remain unresolved. Late registration limits verification of prespecified analyses.

This is a human exposure/materials lead, not evidence of faster alignment, better root safety, successful retention or superior biocompatibility. No new U.S. authorization follows from the registration.

Next: Numerical results and finalized manufacturing/method details; a release date is unknown.

Sources: ClinicalTrials.gov · NCT07926035.

Coverage and remaining gaps: Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved. Twenty-six named records, 28 recent registry records and 382 paper-search records retrieved; the broader registry query timed out. Laser RCT full text, complete harms and registry match remain gaps. A newly posted nanosilver-fluoride orthodontic-band protocol has no results and is not evidence of caries prevention. TRG035 Phase 2 actual dosing remains unverified. Root resorption, caries, occlusion and long-term retention cannot be inferred from material or early-alignment measurements.

Informal-source coverage: Searched indexed tooth-regrowth and orthodontic Reddit/talk/podcast leads. Recent TRG035 posts repeated earlier aspirations without verified human functional tooth regrowth or new trial results. Aligner-material interview audio was not fully appraised; no selected new specific rumor.

Full coverage record.

Source date: 2026-11-04. Recorded in this review: November 6, 2026. Historical baseline; not a new-news alert.

New-to-watch baseline: NCT07916012 was first registered November 4, after its September 28, 2025 actual completion. Thirty-six adults were randomized to directly 3D-printed retainers, positive-pressure thermoformed retainers or vacuum-pressure thermoformed retainers after orthodontic treatment.

Six-month measures include Little’s irregularity index and arch widths in millimeters, with patient satisfaction. No results are posted. A registration and manufacturing method do not establish less relapse, better root/gum health, long-term retention or superior material safety. The record’s broad masking label also needs protocol clarification because the appliances may be distinguishable.

This is an older completed study made visible through a new registration, not a new 2026 treatment start or clinical readout. No new U.S. authorization or dependable publication date follows.

Sources: ClinicalTrials.gov · NCT07916012.

Coverage and remaining gaps: focused_incomplete; Focused/incomplete: retrieved records and selective appraisal do not equal complete worldwide trial, paper, regulator, device/procedure, safety or informal-source coverage. Preserve full successful-check timestamps and baseline flags.; Printedretainer record is retrospective completedstudy without outcomes. AIsegmentation NCT07919652 measures scan accuracy/processingtime (155actual), not clinicalbitequality or total treatmentduration; noresults. Discision NCT07920276 (24planned, randomizedsplitmouth) measures canine movement10weeks, not whole-course/root/gum/relapse outcomes; registrationretrospective and noresults. Toregem index still leads Oct20exhibitionnews; no verified newTRG035dose or human toothregrowth outcome. Directprinted/shape-memory and safety follow-up internationalcensus incomplete.

Informal-source coverage: Toregem originalindex and indexed orthodontic/dentalregeneration podcasts/talks sampled. Older CandidPro/podcastdescriptions concern planning/monitoring, not newly reported controlled whole-course benefit. Original audio/Japan registry appraisal remains unfinished; no new selected availability rumor.

Full coverage record.

Source date: 2026-10-30. Recorded in this review: November 3, 2026.

NCT05905224 first posted results October 30: 45 adults were randomized to seven-day standard-activation aligners (22) or three-day reduced-activation aligners (23). Seven noncompliant/poor-tracking participants were excluded, leaving 19 per arm. Wear hours were the same 20–22 daily.

Reported median treatment duration was 140 days (IQR 102–186) versus 175 days (123–238), and visits 3 (IQR 3–4) versus 5 (3–6), seven-day versus three-day. No statistical comparisons were posted; these values do not show shorter completed treatment with frequent changes.

Two similarly described primary accuracy rows conflict: 0.50 versus 0.43 mm and 0.40 versus 0.45 mm, respectively. A planned movement-rate endpoint was not collected because the required ScanBox was unavailable. The record therefore cannot support a clean accuracy/speed claim. Zero serious/other adverse events were reported for 19 completers per arm, not all 45 randomized people. Root/gum health and long-term relapse were not established; the registry's unit is days despite a duration title saying months.

U.S. status: No new U.S. authorization follows from this study or registration.

Sources: ClinicalTrials.gov · NCT05905224; ClinicalTrials.gov · NCT05905224.

Source date: 2026-11-02. Recorded in this review: November 3, 2026.

First posted November 2, cSPACE/NCT07911176 plans 300 children with severe crowding. Three strategies compare early first-premolar extraction with observation and later braces only if needed; early extraction with planned braces; and conventional later extraction with braces. The primary outcome is final Peer Assessment Rating bite quality at age 18.

Root length, early caries, tooth movement, treatment need, quality of life, treatment duration, visits and costs are separate planned outcomes. This tests an irreversible treatment strategy over years, not faster aligner manufacture. The registry eligibility spans ages 8–19 and its narrative describes different decision ages; detailed eligibility and treatment criteria require the full protocol.

It remains not yet recruiting. Start March 1, 2027, primary completion March 1, 2034 and final completion March 1, 2036 are registry estimates. No efficacy, safety or reduced-treatment-burden conclusion is available yet.

U.S. status: No new U.S. authorization follows from this study or registration.

Next milestones: cSPACE estimated start: 2027-03-01 (Registry estimate; not yet recruiting); cSPACE primary completion: 2034-03-01 (Registry estimate; no result-release commitment).

Sources: ClinicalTrials.gov · NCT07911176.

Coverage and remaining gaps: focused_incomplete; do not advance full successful-check timestamp. Complete retrieval for these bounded queries is not complete worldwide clinical appraisal. Full international registry, conference, device/procedure, detailed safety and audio coverage remains incomplete.; NCT05905224 reports conflicting duplicate mandibular-accuracy rows, no inferential comparisons, missing planned movement-rate measurement and safety denominators limited to completers. Root/gum and long-term retention outcomes remain absent.; Direct-printed/shape-memory complete-treatment and retainer census incomplete. Toregem news index remains October 20 exhibition news; no new TRG035 actual dosing or human tooth-regrowth efficacy verified. New cSPACE very long-term estimates are not result-release dates.

Informal-source coverage: Toregem original news index and indexed dental-regeneration podcasts revisited. Older podcast descriptions concern preclinical enamel/tooth work or repeat existing TRG035 milestones. No new selected availability/dosing rumor; full recordings and Japan registry appraisal incomplete.

Full coverage record.

Source date: 2026-10-29. Recorded in this review: October 30, 2026.

An October 29 retrospective study describes 344 clear-aligner patients who underwent interproximal enamel reduction. Across 4,800 proximal tooth surfaces, caries was detected on 66 surfaces in 36 patients. These are clustered surfaces within people, not 4,800 independent participants.

The reduction categories refer to the combined adjacent contact area: up to 1.0 mm per contact, equivalent to 0.5 mm per tooth surface. The analysis modeled surface-level outcomes with patient clustering. The abstract describes a selected low-risk, highly compliant cohort receiving polishing, hygiene and follow-up care.

This does not show whether enamel reduction raises caries risk versus untreated teeth or prove safety equivalence. Follow-up duration, full adjusted estimates/intervals and root/gum outcomes were unavailable in the appraised abstract; the publisher full text was inaccessible. The observations cannot establish shorter orthodontic treatment, improved final bite or long-term retention. No new U.S. authorization follows.

U.S. status: No new U.S. drug/device authorization; procedural safety observations only.

Next milestones: Full estimates and longer-term enamel/root/gum follow-up: date unknown (No verified date).

Sources: PubMed · PMID 42958839; DOI · 10.1177/14653125261498917.

Coverage and remaining gaps: focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; Full enamel-reduction cohort follow-up duration, estimates/intervals and root/gum outcomes remain behind publisher access.; New root-shortening NCT07906951 and bite-raiser NCT07907263 registrations describe completed earlier studies without results; not new2026 efficacy. New MIH restorative studies NCT07906236/NCT07906548 remain protocols.; Full directly printed/shape-memory, remote-monitoring, final bite and retention census incomplete.

Informal-source coverage: Original Toregem news index and indexed dental/regeneration podcast/Reddit leads sampled. Latest Toregem announcement remains October20 exhibition news, not dosing. The Richard Miron regenerative-dentistry podcast index was a lead, without full transcript appraisal; no new selected development rumor or verified2030 availability.

Full coverage record.

Source date: 2026-10-27. Recorded in this review: October 27, 2026.

First posted October 27, NCT07897864 plans 30 adults with mild-to-moderate lower-front crowding, randomized 15/15 to directly bonded bracketless 3D-BOT E-WIRE or conventional fixed braces. This is a wire/composite system, not a clear aligner.

The main outcome tracks Little's Irregularity Index through week 24. Secondary measures include root shortening, alveolar bone, gum bleeding/plaque, appliance failures, pain, patient experience and cumulative clinical/preparation time. The appliance is visible, so treatment and outcome assessment cannot be assumed fully blinded; the statistician receives coded groups.

The trial is not yet recruiting. Start November 15, 2026, primary completion June 15, 2028 and final completion December 15, 2028 are registry estimates. Faster early alignment, fewer visits or reduced chair time would not establish a shorter completed orthodontic course, superior final bite or long-term retention. There are no results or new U.S. clearance claims.

U.S. status: No new U.S. authorization verified from this registration.

Next milestones: 3D-BOT randomized trial start: 2026-11-15 (Registry estimate; not yet recruiting); 3D-BOT primary completion: 2028-06-15 (Registry estimate, not a promised publication date); 3D-BOT final completion: 2028-12-15 (Registry estimate).

Sources: ClinicalTrials.gov · NCT07897864.

Coverage and remaining gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; No complete global coverage of orthodontic materials, directly printed/shape-memory appliances, remote monitoring, treatment acceleration or long-term retention.; Aligner BPA/BPS saliva study PMID42905298 was abstract-appraised only: a biomarker concentration does not establish appliance origin, systemic dose or clinical harm.; New FM clear-aligner single-arm registration NCT07896369 surfaced but was not fully appraised. Root/gum and final-bite/retention outcomes should remain separate from manufacturing speed and early movement.; No complete primary-source confirmation of rumored 2030 tooth-regrowth availability; congenital tooth agenesis is distinct from acquired loss.

Informal-source coverage: scope: Original Toregem index, viral/removed Reddit tooth-regrowth posts and indexed regeneration/3D-printing podcast leads sampled.; status: No selected new rumor/status change. Repeated 2030 availability hopes are not sponsor-confirmed access; October 20 exhibition news is not a dosing or efficacy milestone.; limitations: Removed originals and absent full audio/transcripts limit attribution; do not invent content.

Full coverage record.

First published online: October 17, 2026. Evidence: randomized controlled human study, NCT07176871; primary abstract appraised.

Forty-six extraction-treatment patients were randomized to heat-activated or conventional nickel-titanium archwire sequences; 44 completed, 22 per group. Early tooth-irregularity reduction favored heat-activated wires at months 1–3, but six-month alignment rates did not significantly differ (1.35 versus 1.30 mm/month). Reported pain was lower with heat-activated wires, without numerical pain effects or uncertainty intervals in the accessible abstract.

Safety and limits: No between-group root-length or alveolar-bone difference was detected; the small study does not establish safety equivalence. Two participants discontinued, one per group. The September 2025 registry reports 52 actually enrolled versus the paper's 46 randomized; that discrepancy is unresolved. Registration was first posted after the listed July 2025 completion. Full harms, complete statistical methods and root/bone estimates remain behind publisher access. Initial alignment is one phase of orthodontics; the trial does not establish shorter total treatment or durable retention, and it does not compare aligners with braces.

U.S. status and next: This is a materials comparison, not a new U.S. approval. Full-course duration, final bite and longer root/gum/retention follow-up remain undated.

Sources: PubMed · PMID 42888967; DOI · 10.1177/14653125261493138; ClinicalTrials.gov · NCT07176871.

Coverage and remaining gaps: Read the current authoritative topic and watch scope. September 5–October 20 window retains overlap from the September 12 full successful check; changes since October 16 prioritized and prior canonical findings deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (162 records) and all 12 saved named records. Incidental matches excluded. Full successful-check timestamp must remain unchanged.; Exact-phrase Europe PMC MED discovery retrieved 242 of 242 returned records, with selective title/abstract appraisal. An initial unquoted search produced incidental broad matches and was replaced with these complete bounded exact-phrase queries. Retrieval is not exhaustive worldwide full-text appraisal.; International registry census, every device/procedure, complete conference appendices, all full safety tables and original podcast/audio coverage remain incomplete. No additional selected finding is not a full-topic no-news conclusion.; Toregem news index now includes October 20/October 6 exhibition items but no verified new TRG035 dosing or efficacy beyond August 17 trial-notification review. Formal new Boston University NCT07881146 attachment cohort plans 18, not yet recruiting, December 2026 / December 2027 estimates, no results; units for translation/vertical displacement and 18-month retention window versus 12-month completion need clarification. New late-registered completed gingival/orthodontic cohorts have no posted results and do not establish new efficacy.; Original NCT07176871 cross-check now retrieved: completed July 1, 2025, retrospectively registered September 16, 2025, 52 actually enrolled versus publication 46 randomized/44 completing. Difference retained rather than silently harmonized. NCT07883005 SALI-10 supportive-care DIAMOND Phase3 planned288, not yet recruiting, November1,2026start/November1,2031completion estimates; no outcomes or tooth regeneration. Lead reviewed, not selected as a new efficacy item.; October 23 delta: Toregem index retains October20 exhibition news, without a selected clinical dosing/efficacy announcement. New topical/nanohydrogel registry-mirror leads have no appraised outcomes; enamel reports in extracted teeth remain in vitro and were excluded from human clinical efficacy. No full registry/literature census repeated.

Informal-source coverage: Targeted indexed Reddit, named-program and talk/podcast queries were reviewed. Routine self-experimentation, clinic advertising and repeated existing source claims were not treated as formal outcomes. Unindexed comments and original audio remain coverage gaps. October 23 delta remains a bounded indexed-source check; no newly selected material rumor status change. Original audio and unindexed comments remain incomplete.

Full coverage record.

Baseline context, not new October news. This paper appeared online May 28, 2026 despite an October journal issue. It followed 48 people with Stage IV periodontitis and one severely compromised, displaced non-molar tooth each after periodontal regenerative surgery, later orthodontics and tailored supportive periodontal care.

Thirty-three participants completed 20-year follow-up. Estimated test-tooth survival was 89.1% (CI 79.4–99.9); complication-free probability was 86.3% (CI 75.7–98.3). Five test teeth had complications—one pulp necrosis, two root fractures and two periodontal recurrences—and four were extracted.

Limits and practical meaning: This uncontrolled selected cohort cannot separate the effects of surgery, orthodontics and continuing care, or establish superiority to extraction/implant strategies. Attrition was 31.2%; sensitivity scenarios ranged from 60.4% to 91.7% tooth survival depending on missing participants. The finding concerns preservation of existing teeth and periodontal support, not growing new teeth or proving a novel U.S. indication. Further comparative follow-up has no verified date.

Sources: DOI · 10.1016/j.jdent.2026.106799; PubMed · PMID 42214655.

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (152 returned records) and all 12 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; Appraised an older May 28 online 20-year periodontal-regeneration/orthodontics cohort despite its October issue. Baseline context only, not new October news; valuable because it measures tooth survival and complications rather than a regeneration marker.; October 15 EV registry update NCT07867067 remains not yet recruiting, 22 planned, no results; affiliation/formatting changes do not establish treatment. Other October 14–16 small registrations include orthodontic acceleration, bracket bone/root outcomes, extraction-site volume preservation and endodontics; no outcomes. Untested ridge preservation is not whole-tooth regeneration.; SLCTR/2026/026 ALIGN-PBM is pending, 34 planned in Oman, October 15 anticipated start with no first-enrollment date; it studies pain after aligner change, not total treatment duration, final bite, root/gum health or retention. Formal registry checked as a discovery example, not an efficacy claim.; Toregem primary Japanese Phase 1/2 record, first Phase IIa dosing, every directly printed/shape-memory aligner program, long-term retention and root/gum safety, and complete new-tooth efficacy remain unresolved.

Informal-source coverage: October 9 Very Dental Marco Maiolino episode description and October 13 ADA Smart AI episode listing inspected. These discuss preservation/workflows, not newly measured regeneration or orthodontic benefit; no timestamped result claim extracted and full audio/transcript not reviewed. Old tooth-regrowth launch forecasts remain unconfirmed.

Full coverage record.

Protocol published October 7, 2026; newly appraised October 13. NCT07664046 plans 75 adolescents aged>10 and<18 with noncavitated smooth-surface enamel white-spot lesions. Three randomized groups receive one P11-4 application plus fluoride varnish, applications at baseline/3 months plus varnish, or varnish alone. QLF assessments are blinded; multiple lesions within patients are handled by mixed models. Fixed-appliance patients and cavitated lesions are excluded, limiting direct application to post-orthodontic lesions or missing tooth structure.

No results or observed harms are reported. The paper designates the 6-month ΔQ lesion-volume comparison between repeated/single treatment as primary; the June 23 registry instead lists ΔF and ΔQ changes at 12 months. Its effect-size assumption comes from P11-4-versus-fluoride evidence, not the actual repeated-versus-single contrast. These differences need reconciliation before interpreting later results.

Timing: Registry remains recruiting, actual start February 2, 2026, estimated primary October 31, 2027 and final December 14, 2027. Paper abstract expects July 2027 completion; its later results wording is also ambiguous. Neither is a promised publication date. U.S.: no new formulation-specific authorization established. Next: protocol/registry alignment, then controlled clinical durability and safety; fluorescence remineralization is not replacement of lost enamel.

Full protocol; original registry.

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (134 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; Recovered October 7 P11-4 full protocol and June 23 original record; primary endpoint and estimated finish mismatch retained. Toregem news ends October 6 BioJapan business announcement; actual PhaseIIa dosing and human tooth-regrowth efficacy unverified. Printed-aligner September 24 paper, OrthoPulse and stale NCT07496892 deduplicated. October 9 power-arm/miniscrew/bone-mixture registrations disclose completed/planned trials without outcomes, not comparative efficacy. Complete Japanese jRCT PhaseIIa record, alignment/root/gum/retention and full repair/regeneration census remain gaps.

Informal-source coverage: October 9 intrestingtoknow repost and October 12 askdentists question repeat TRG035/2030 timelines and extrapolate to acquired tooth loss; sponsor business-news page does not verify first dosing or efficacy. Reposts are not independent confirmation. Full dental/orthodontic recordings and Japanese originals incomplete; no fresh rumor alert.

Full coverage record.

Source date: October 9, 2026 first registry posting.

Ain Shams University's NCT07867067 plans 22 adults aged 20–40 with persistent intrabony periodontal defects after initial therapy. The randomized, masked Phase 2 protocol compares a beta-tricalcium-phosphate scaffold/collagen membrane with or without small extracellular vesicles cultured from the participant's own gingival mesenchymal cells. Six-month radiographic bone fill is primary; attachment gain, early healing and local adverse effects are secondary. No results are posted.

Status and limits: Not yet recruiting despite an elapsed October 1 estimated start. Primary/final completion May 1/November 1, 2027 are estimates. Small size, imaging endpoints and short follow-up cannot establish histological regeneration, durable tooth retention, whole-tooth regrowth or long-term cellular-product safety. Structured arm numbering differs from the narrative; clarify the final allocation and protocol before result appraisal. No U.S. authorization for this adjunct is established. Next: actual start, product-quality/harms data and a complete controlled report; publication date unknown.

Original registry.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (288 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; P11-4 official abstract https://sciforum.net/paper/34045 remains the same October2 material already appraised; conference October7–9 does not prove extra results or actual delivery. Direct printed-aligner September24 publication and registry status deduplicated. NCT07496892 still not yet recruiting with stale elapsed estimates; OrthoPulse status unchanged.; Toregem news now has October6 BioJapan business presence but no PhaseIIa first dosing/results verification. Japanese original jRCT matched PhaseIIa and complete PhaseI numerical safety remain unresolved. Numerous new October6–9 retrospective/historical bracket-bonding, mouthrinse, pulpotomy and movement records lack outcomes; their registration was not relabeled as new demonstrated clinical benefit. Full alignment/root/gum/final-bite/retention and new-tooth/repair census remains incomplete.

Informal-source coverage: Saved https://www.reddit.com/r/Biohackers/comments/1wq1adh/910_dentists_probably_wont_recommend_this/ and October4 https://www.reddit.com/r/ITOI/comments/1wxkmlv/japan_is_trialing_a_drug_that_regrows_human_teeth/ repeat older TRG035/2030 expectations and extrapolate to acquired missing teeth. No new controlled human result or verified phaseIIa dose followed. Fresh comment activity is not independent confirmation. No new rumor selected; full orthodontic/tooth-regrowth recordings not appraised.

Full coverage record.

Source date: October 2, 2026 abstract publication. Meeting: October 7–9 online dentistry conference.

A 45-person randomized post-orthodontic white-spot-lesion study compares P11-4, fluoride varnish and no treatment in adults aged 18–30, followed six and twelve months. The abstract reports a fluorescence ΔF advantage over varnish (p<.001), but no P11-4-versus-varnish ICDAS difference, and no lesion-area advantage over untreated controls. Its own conclusion says visible masking was similar. Effect sizes, confidence intervals and usable safety counts are absent; QLF is a mineralization surrogate, not replacement of missing enamel. A matching investigator/title/intervention registry, NCT06749977, describes a 2020–2023 study registered in December 2024. This is newly available conference material, not a newly completed trial; registry assessment times also need reconciliation with the abstract. Next: full report, safety/disposition, and replication; the October 7–9 presentation is scheduled, not guaranteed new data. No new U.S. formulation-specific authorization established.

Official abstract; matching original registry.

Source/event date: September 25, 2026 first posting; recovered October 6.

NCT07842120 is a recruiting randomized Phase 2 study of 60 planned participants comparing micro-osteoperforation, local prostaglandin E1, local calcitriol and control. The primary endpoint is mandibular anterior alignment measured by Little's Irregularity Index at six months. It reports an actual April 16 start, predating registration; primary completion December 30, 2026 and final February 2027 are estimates. No results or comparative harms are posted. Short-segment movement cannot establish a shorter whole orthodontic course, better final occlusion, preserved roots/gums or durable retention. The registry's masking claim needs protocol appraisal because an invasive procedure and local injections may be distinguishable. This is formal human investigation, not a validated routine acceleration protocol or new U.S. drug indication. Next: protocol, full-course/root/gum outcomes and actual results; no promised publication day.

Original registry.

Source date: October 5, 2026 first registry posting. Reported actual study completion: July 10, 2026.

NCT07859358, Assiut University, discloses a completed randomized participant-masked Phase 1/2 study in 24 adults with Stage II periodontitis. Scaling/root planing is paired with injectable platelet-rich fibrin, peroxoborate oxygen-releasing gel or saline control. Planned primary measures are clinical attachment, pocket depth and bleeding through 12 weeks. No results are posted. Registration followed completion; the reported March 10 primary-completion date also needs reconciliation with January 20 start and the 12-week primary endpoint. These measures do not by themselves establish regenerated periodontal structure, long-term tooth retention or whole-tooth regrowth. No U.S. indication/availability claim is established. Next: full controlled outcome/harms report and timing clarification; publication date unknown.

Original registry.

Source/event date: 2026-09-24. Evidence: Peer-reviewed randomized trial abstract plus registry; full text not appraised.

A September 24 publication reports the previously watched NCT06685029 trial: 52 participants randomized among directly printed aligners, Invisalign, ClearCorrect and fixed appliances. Treatment durations were 6.59±1.42, 5.36±1.63, 5.72±1.88 and 10.16±2.28 months, respectively; the fixed-appliance group took longer than each aligner group (p<0.001). The abstract does not establish direct printing as faster than other aligners. Between-group differences in salivary BPA and percentage PAR bite-score improvement were not significant; that does not prove equivalent toxicity or final bite quality. The registry restricts interpretation to ages 15–24 with non-extraction Class I mild-to-moderate crowding (0–6 mm) and healthy periodontium. Root/gum outcomes and long-term retention remain unanswered. Registration occurred after the study began; registry results are still absent, but a publication is now available. The abstract reports no harmful effects without detailed event counts. Publication; registry.

Next milestone: Independent replication and retention follow-up: no announced date verified.

Publication; DOI · 10.1007/s00056-026-00690-6; ClinicalTrials.gov · NCT06685029.

Source date: 2026-09-28. Evidence: peer-reviewed prospective comparative cohort.

A clinician-supervised photo-monitoring pathway plus caregiver education was associated with fewer recorded problems during childhood palate expansion. One Italian center enrolled 100 children aged 7–11: 50 caregiver-selected telemonitoring, 50 conventional weekly office follow-up. Recorded complications: 12/50 (24%) versus 23/50 (46%); unadjusted RR 0.52 (95% CI 0.29–0.93). All completed follow-up. Unscheduled visits: 12% versus 20%, RR 0.60 (0.24–1.53), not significant.

Limitations: Nonrandomized self-selection, unequal opportunities to detect transient problems, unmeasured caregiver differences and no adjusted analysis. Education and monitoring cannot be separated. Total visits, whole-course duration, final bite, roots and long-term retention were not established.

Safety: No documented delayed detection in either small cohort does not prove equivalent safety. Photo review retained in-person assessments and escalation when needed.

U.S. status: No regulatory action; evidence concerns a clinical follow-up pathway.

Next milestone: Randomized multicenter replication and longer retention follow-up remain undated.

Original full study.

Source date: 2026-09-18. Event date: 2026-09-18. Evidence: peer-reviewed randomized human study; full text and registry appraised.

Two cements had similar observed two-year outcomes after partial pulpotomy, a tooth-preserving procedure; the study did not demonstrate regrowth of missing teeth. A single-center, single-operator Spanish study reports 139 treated permanent molars: success in 58/64 (90.6%) with White MTA Angelus and 69/75 (92.0%) with NeoPutty at 24 months, p=.774. All 139 reportedly completed follow-up. The comparison was designed for superiority, so the null result does not prove equivalence.

Limitations: The 24-month assessment extended the initial follow-up. Important unresolved registry discrepancies: NCT06881615 lists 71 actually enrolled, versus 139 in the paper, and was first posted after study completion. These inconsistencies reduce confidence in prospective reporting; longer-term structural preservation remains uncertain.

Safety: Twelve failures required conventional root-canal treatment. The paper does not provide a separate comprehensive adverse-event table.

U.S. status: No new U.S. authorization or indication is established by this publication.

Next milestone: Resolve paper–registry discrepancies; longer multicenter comparative follow-up has no announced date.

Original open-access study; Primary trial registry.

Source date: 2026-09-15. Event date: 2026-09-15. Evidence: peer-reviewed randomized controlled human trial; abstract and registry appraised.

Adding wear-time monitoring did not significantly improve satisfaction, shorten treatment or increase successful bite correction. NCT05213338: publication reports 58 adolescents aged 10–15 using twin-block or headgear activator appliances, randomized to feedback from thermosensitive wear sensors or no monitoring. Investigators used intention-to-treat and per-protocol analyses; dropout was 21%.

Limitations: One center, no patient/clinician blinding. The current registry lists 52 enrolled versus 58 in the paper; unresolved. The 13-month treatment figure applies only to 39 successful cases, not a randomized between-arm advantage. Findings concern these removable functional appliances, not all AI/remote monitoring.

Safety: No harms detected in the abstract; full adverse-event reporting not appraised.

U.S. status: No new U.S. authorization; a monitoring technology does not automatically improve treatment.

Next milestone: Replication, longer-term stability and full-data appraisal undated.

Original paper abstract; Original DOI; Registry.

Source date: 2026-09-11. Event date: 2026-09-11. Evidence: peer-reviewed retrospective comparative cohort; original abstract appraised.

A small private-practice comparison found shorter treatment with customized ceramic brackets, alongside substantially more bracket failures. Seventy-five patients: LightForce 36, conventional appliances 39. Treatment duration was 16 versus 19 months; at least one bracket failure occurred in 80.6% versus 43.6%. Scheduled visits were fewer but bracket-related emergency visits more frequent with LightForce. Final total ABO-OGS scores were 29 versus 25, p=.061; marginal-ridge scores were worse with LightForce.

Limitations: Retrospective, nonrandomized, one practice. Similar baseline severity does not remove selection/confounding. Nonsignificant final-score difference is not proof of equivalence. No long-term retention or comprehensive root/gum analysis.

Safety: Bracket failures and extra emergency visits are meaningful treatment burdens; long-term safety not established.

U.S. status: No new approval or product-availability conclusion.

Next milestone: Prospective replication and retention follow-up undated.

Original abstract; Original DOI.

Source date: 2026-09-09. Event date: 2026-09-09. Evidence: peer-reviewed nonrandomized prospective human pilot; abstract appraised.

Surgically accelerated orthodontics had shorter observed treatment than conventional care, but adding dental-pulp stem cells did not show a significant extra bone benefit. Thirty adults selected conventional treatment, corticotomy plus bone allograft, or that surgery plus cultured dental-pulp stem cells in a scaffold. Twenty-two completed: 9, 7 and 6 respectively. Both surgical groups had approximately 13.5 months of treatment versus 24.8 months for controls; added-cell versus graft-only bone-thickness difference was nonsignificant.

Limitations: Patient-preference allocation, small groups and attrition; qualitative CBCT grading. The surgical procedure, graft and cells cannot be credited equally, and nonrandomized duration differences are not proof of causality. No durability/retention conclusion.

Safety: No serious adverse events observed during available follow-up; small study cannot establish cell-product or surgical long-term safety.

U.S. status: Investigational cellular adjunct; no U.S. routine-use authorization verified.

Next milestone: Larger randomized study and long-term follow-up undated.

Original abstract; Original DOI.

Source date: 2026-09-12. Evidence: peer-reviewed pilot randomized human study; abstract reviewed.

A pediatric enamel-defect trial found a pain-sensitivity signal but no superiority over fluoride toothpaste on its mineral-gain endpoint. RBR-6d3g5hp / U1111-1327-7119; triple-blind pilot, 30 children aged 6–12, 95 teeth, 45 days. REFIX Booster versus 1450 ppm fluoride. Between-group change in fluorescence ΔF: −0.43 percentage points, 95% CI −2.73 to 1.86, p=.711; ΔFmax also nonsignificant. Sensitivity improved more, p=.011. Models accounted for teeth clustered within children.

Limitations: Short pilot; fluorescence is a surrogate, not replacement of missing enamel or tooth regeneration. No relevant aesthetic difference; secondary pain signal needs replication.

Safety: No adverse effects reported in this small short study.

U.S. status: No new U.S. authorization or availability established.

Next milestone: Definitive trial and durability follow-up undated.

Original abstract; Original DOI.

Source date: 2026-09-11. Evidence: peer-reviewed randomized human study; accepted early article.

A 60-person extraction trial found early healing and imaging gains with blood-derived concentrates; it did not study new teeth or long-term tooth retention. TCTR20251028003, retrospectively registered. Impacted lower-third-molar extraction; 20 each advanced platelet-rich fibrin, concentrated growth factors, natural healing. Both interventions improved early pain/swelling/healing. At 3 months A-PRF buccal-wall height change +1.32 ± 0.72 mm versus +0.01 ± 1.6 mm with CGF and −0.07 ± 1.12 mm controls; both preserved width.

Limitations: One small extraction setting; accepted version may be edited. Three-month radiographic dimensions do not establish durable functional regeneration or superior implant survival.

Safety: Accessible abstract does not provide a complete adverse-event table.

U.S. status: No new FDA authorization or generalized dental-regeneration claim.

Next milestone: Longer comparative follow-up undated.

Original accepted paper.

Directly printed and shape-memory aligners: registered human comparisons include NCT06685029, comparing direct-printed and conventional aligners with fixed appliances and assessing effectiveness, efficiency and material release, and NCT07496892, comparing movement accuracy of printed and thermoformed aligners. A posted study protocol supports the latter's research scope. The live registry/API was inaccessible at the September 12 baseline; the September 14 review below resolves those record fields. Registration or completion does not establish superiority or universal U.S. availability.

Faster tray changes: an August 22, 2026 randomized study analyzed 38 adults after 45 were randomized and seven excluded for noncompliance. It compared three-day trays with smaller programmed movement against seven-day trays with larger movement. The three-day arm needed more refinements and visits, without a significant improvement in total treatment duration or final occlusion. Thus, this does not support simply changing an existing prescription more frequently. Limitations include the small single-center population, exclusions after randomization and a missing usable registration ID in the abstract. Primary paper.

DentalMonitoring: a randomized trial of 56 patients found about 1.5 fewer appointments with remote monitoring, but treatment lasted about 1.9 months longer; refinement and total-aligner counts did not significantly differ. It involved one orthodontist and could not blind participants or clinicians. This is a useful baseline for evaluating later AI-monitoring claims. Trial paper; ACTRN12620000475943.

Photobiomodulation: keep OrthoPulse tooth-movement/treatment-time study NCT02954133 and pain study NCT05361616 on the named watch. Pain relief is a separate endpoint from acceleration. Registry status was not recovered at the September 12 baseline and is updated below. No efficacy or speed conclusion is inferred from registration or completion alone.

Retention: a five-year randomized study initially enrolled 104 adolescents comparing lower removable vacuum-formed retainers with bonded retainers, while both groups used upper removable retainers. Lower-tooth alignment favored bonded retention, with attrition and the adolescent population limiting generalization. Continue following CAD/CAM retainers, long-term relapse, breakage and periodontal outcomes rather than assuming a newer retainer design is better. Five-year primary study.

P11-4 self-assembling peptide: a January 2026 triple-blind trial randomized 25 adolescents receiving fixed orthodontics to peptide-plus-fluoride gel or fluoride gel alone. At 18 months, initial lesions affected 7.2% versus 14.5% of evaluated surfaces. This is encouraging prevention/remineralization evidence, but surfaces are not independent patients and patient-level power was limited. It does not demonstrate regrowth of missing chunks of enamel. Exact formulation and U.S. regulatory claims require product-specific verification. Primary study; DRKS00028048.

Periodontal regeneration: recombinant FGF-2/trafermin and enamel matrix derivatives provide established human trial comparators for future programs. In one phase III trial, FGF-2 improved radiographic bone fill, while the other co-primary endpoint—clinical attachment gain—did not significantly differ from placebo. Keep bone fill, gum attachment and long-term tooth retention distinct. New indications, delivery systems and cell-based approaches are in scope when human studies appear. Phase III primary publication. This older evidence is baseline context; current U.S. product availability was not established here.

TRG035 / anti-USAG-1, Toregem: the sponsor announced on August 17, 2026 that Japan's PMDA completed review of the clinical-trial notification for an exploratory phase IIa study in congenital tooth agenesis. This is permission-related trial progress, not marketing approval or demonstrated human tooth regrowth. The next important events are verified enrollment/dosing and controlled efficacy data, followed by any study specifically addressing acquired adult tooth loss. A U.S. approval or availability date was not identified. Dated sponsor announcement.